We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Skepticism of User Fees Highlighted in New PwC Report
Industry Skepticism of User Fees Highlighted in New PwC Report
December 3, 2010
As the FDA continues its negotiations with industry in advance of the reauthorization of the Prescription Drug User Fee Act (PDUFA), a new survey is highlighting drugmakers’ skepticism of the fees’ effectiveness and reinforcing calls for more frequent communication with the agency.